CARLSBAD, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced a partnership with Emiliem, Inc. to screen the company’s multi-kinase inhibitors using Invitrogen’s SelectScreen™ platform. Invitrogen will perform biochemical kinase screening, cellular pathway profiling and P450 screening of Emiliem’s compounds targeting cancer. Financial details of the multi-year agreement were not disclosed.
